ProMetic Presents Preclinical Data for Prostate and Pancreatic Cancer at the AACR Meeting

MONTREAL, CANADA, Apr 17 (MARKET WIRE) --
ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced results of
three compounds in preclinical studies for prostate and pancreatic cancer
at the American Association for Cancer Research ("AACR") Annual Meeting
2008 being held in San Diego this week.

Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessions
as follows:

Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data on
PBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayed
significant antitumor activity in human prostate cancer both in vitro and
in vivo. The in vivo study demonstrated a significant reduction in tumor
volume both alone (p less than 0.05) and in combination with
cyclophosphamide (p less than 0.01).

Dr. Lyne Gagnon, ProMetic's Director of Research and Development,
Biology, presented preclinical data on the PBI-0110 alone and in
combination with gemcitabine in intradermal and orthotopic pancreatic
cancer. The study showed that PBI-0110 alone significantly inhibited
pancreatic tumor growth in mouse models by as much as 58 percent (p less
than 0.05) after 44 days. The study also demonstrated a dose dependent
inhibition of tumor growth, with the 400mg/kg dose being the most
effective, inhibiting growth by nearly 40 percent after 25 days (p less
than 0.05). Combination therapy of 100mg/kg PBI-0110 and gemcitabine
demonstrated similar efficacy. Finally, the study demonstrated increased
survival in mice that received the combination therapy of PBI-0110
200mg/kg and gemcitabine.

Finally, Dr. Brigitte Grouix, ProMetic research scientist, presented data
on PBI-1308, which demonstrated a reduction of inflammation and cancer
cell proliferation through inhibition of NF-kappaB in prostate cancer and
inhibition of TNF-alpha, and inflammatory cytokine.

"We continue to be very proud of the progress our compounds are making in
early-stage cancer research," said Pierre Laurin, president and CEO of
ProMetic Life Sciences, Inc. "We are assembling a broad pipeline of
promising candidates for various cancers, which augments PBI-1402, our
lead compound which has shown compelling human data for the treatment of
chemotherapy-induced anemia."

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and
marketing of a variety of commercial applications derived from its
proprietary Mimetic Ligand(TM) technology. This technology is used in
large-scale purification of biologics and the elimination of pathogens.
ProMetic is also active in therapeutic drug development with the mission
to bring to market effective, innovative, lower cost, less toxic products
for the treatment of hematology and cancer. Its drug discovery platform
is focused on replacing complex, expensive proteins with synthetic
"drug-like" protein mimetics. Headquartered in Montreal (Canada),
ProMetic has R&D facilities in the U.K., the U.S. and Canada,
manufacturing facilities in the U.K. and business development activities
in the U.S., Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and
uncertainties. These statements are "forward-looking" because they are
based on our current expectations about the markets we operate in and on
various estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking statements if
known or unknown risks affect our business, or if our estimates or
assumptions turn out to be inaccurate. Such risks and assumptions
include, but are not limited to, ProMetic's ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects,
the successful and timely completion of clinical studies, the ability of
ProMetic to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process
and general changes in economic conditions. You will find a more detailed
assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2007, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to
update any forward-looking statement even if new information becomes
available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations.

Contacts:
ProMetic Life Sciences Inc.
Pierre Laurin
President and CEO
1-514-341-2115
p.laurin@prometic.com

ProMetic Life Sciences Inc.
Anne Leduc
Manager, Investor Relations & Communications
1-514-341-2115
a.leduc@prometic.com

Echoes Financial Network Inc.
Dominic Sicotte
1-514-842-9551
dsicotte@echoesfinancial.com

Lippert / Heilshorn & Associates
Bruce Voss
Investor Relations
1-310-691-7100

Lippert / Heilshorn & Associates
Kim Golodetz
1-212-838-3777
KGolodetz@lhai.com

Lippert / Heilshorn & Associates
Jules Abraham
Media Relations
1-212-838-3777
JAbraham@lhai.com

Copyright 2008, Market Wire, All rights reserved.

-0-